

DNAH5 Mutations Are a Common Cause of Primary Ciliary Dyskinesia with Outer Dynein Arm Defects

Nada Hornef, Heike Olbrich, Judit Horvath, Maimoona A. Zariwala, Manfred Fliegau, Niki Tomas Loges, Johannes Wildhaber, Peadar G. Noone, Marcus Kennedy, Stylianos E. Antonarakis, Jean-Louis Blouin, Lucia Bartoloni, Thomas Nüsslein, Peter Ahrens, Matthias Gries, Heiner Kuhl, Ralf Sudbrak, Michael R. Knowles, Richard Reinhardt, and Heymut Omran

Department of Pediatrics and Adolescent Medicine, University Hospital Freiburg, Freiburg; Children's Hospital of the Ruhr University Bochum, Bochum; Darmstädter Kinderkliniken Prinzessin Margaret, Darmstadt; Dr. von Haunersches Kinderspital, Ludwig-Maximilians University, Munich; Max-Planck Institute for Molecular Genetics, Berlin, Germany; Department of Medicine, University of North Carolina, Chapel Hill, North Carolina; Department of Respiratory Medicine, University Children's Hospital, Zurich; and Department of Genetic Medicine and Development, University of Geneva Medical School, and University Hospitals of Geneva, Geneva, Switzerland

Rationale: Primary ciliary dyskinesia (PCD) is characterized by recurrent airway infections and randomization of left–right body asymmetry. To date, autosomal recessive mutations have only been identified in a small number of patients involving *DNAI1* and *DNAH5*, which encode outer dynein arm components.

Methods: We screened 109 white PCD families originating from Europe and North America for presence of *DNAH5* mutations by haplotype analyses and/or sequencing.

Results: Haplotype analyses excluded linkage in 26 families. In 30 PCD families, we identified 33 novel (12 nonsense, 8 frameshift, 5 splicing, and 8 missense mutations) and two known *DNAH5* mutations. We observed clustering of mutations within five exons harboring 27 mutant alleles (52%) of the 52 detected mutant alleles. Interestingly, 6 (32%) of 19 PCD families with *DNAH5* mutations from North America carry the novel founder mutation 10815delT. Electron microscopic analyses in 22 patients with PCD with mutations invariably detected outer dynein arm ciliary defects. High-resolution immunofluorescence imaging of respiratory epithelial cells from eight patients with *DNAH5* mutations showed mislocalization of mutant *DNAH5* and accumulation at the microtubule organizing centers. Mutant *DNAH5* was absent throughout the ciliary axoneme in seven patients and remained detectable in the proximal ciliary axoneme in one patient carrying compound heterozygous splicing mutations at the 3'-end (IVS75-2A>T, IVS76+5G>A). In a preselected subpopulation with documented outer dynein arm defects ($n = 47$), *DNAH5* mutations were identified in 53% of patients. **Conclusions:** *DNAH5* is frequently mutated in patients with PCD exhibiting outer dynein arm defects and mutations cluster in five exons.

Keywords: cilia; *DNAH5*; outer dynein arm; primary ciliary dyskinesia

Primary ciliary dyskinesia (PCD; Mendelian Inheritance in Man [MIM] 242650) is estimated to affect 1 in 10,000 to 20,000 individ-

uals (1, 2). The complex PCD phenotype involving various organ systems is explained by dysfunction of motile cilia and flagella, respectively. Recurrent respiratory infections are caused by defective mucociliary clearance due to immotile or dysmotile respiratory cilia (3), resulting in chronic inflammation and bronchiectasis. Dysfunction of monocilia at the embryonic node is associated with randomization of left–right body asymmetry (4), and half of the patients with PCD exhibit situs inversus. PCD plus situs inversus is also referred to as Kartagener's syndrome (MIM 244400). Reduced fertility is often observed in male patients with PCD (5, 6). The inconclusive initial clinical presentation, particularly in children without situs inversus, often delays diagnosis and may cause underestimation of the disease prevalence (7).

Respiratory cilia activity is generated by the action of dynein arm complexes attached to the peripheral axonemal A-microtubules (8–10). In PCD, various ultrastructural defects of the ciliary axoneme have been identified. The most frequent abnormalities comprise the absence of some or all outer dynein arms (ODAs) (3); other defects include inner dynein arm (IDA) defects, microtubule transpositions, and radial spoke defects (11).

PCD represents a heterogeneous group of genetic disorders. In most cases, inheritance is autosomal recessive but other modes of transmission have also been observed. *DNAI1*, the human ortholog of the *Chlamydomonas reinhardtii* gene *IC78*, encodes an intermediate chain of the ODA (12). To date, recessive *DNAI1* mutations have been detected in 6 of 47 studied PCD families (13, 14), and approximately 50% of reported mutant alleles comprise the splicing mutation 219+3insT. Occasionally, mutations in the *RPGR* gene located on the X chromosome, which is responsible for 20% of all retinitis pigmentosa cases, have been found in males with retinal degeneration and PCD (15–17).

Applying a homozygosity mapping strategy, we previously localized a PCD locus to chromosome 5p (18). Using a candidate gene approach, we identified *DNAH5*, which is composed of 79 exons with one alternative first exon. *DNAH5* encodes a heavy chain of the ODA and is the human homolog of the dynein γ -heavy chain of *C. reinhardtii*. Mutational analysis in 25 PCD families in which haplotype analyses were consistent with linkage to the *DNAH5* locus detected recessive mutations in eight PCD families (19). Here, we analyzed additional 109 PCD families with various ultrastructural phenotypes for mutations in *DNAH5*. Considering the previous report of extensive genetic heterogeneity in PCD (20), we unexpectedly found that *DNAH5* mutations are responsible for PCD in 28% of 109 analyzed PCD families. Interestingly, half of PCD families with ODA defects harbored *DNAH5* mutations.

(Received in original form January 20, 2006; accepted in final form April 18, 2006)

Supported by grants from the "Deutsche Forschungsgemeinschaft" (SFB592 and DFG Om 6/2 to H.O.), Bundesministerium für Bildung und Forschung (NGFN-2 01GR0414 to R.S. and R.R.), the National Institutes of Health (K23HL04225 to P.G.N.; RR00046, MRK-HL-R01, MRK U54 to M.R.K.), the Carvajal Foundation (3200B0 to L.B. and J.L.B.), and a Swiss National Science Foundation grant (105838 to J.L.B.). N.H. and J.H. received research grants from the University of Freiburg and the German Academic Exchange Service (DAAD), respectively.

Correspondence and requests for reprints should be addressed to Heymut Omran, M.D., Department of Pediatrics and Adolescent Medicine, Mathildenstrasse 1, 79106 Freiburg, Germany. E-mail: omran@kikli.uni-freiburg.de

This article has an online supplement, which is accessible from this issue's table of contents at www.atsjournals.org

Am J Respir Crit Care Med Vol 174, pp 120–126, 2006
Originally Published in Press as DOI: 10.1164/rccm.200601-0840C on April 20, 2006
Internet address: www.atsjournals.org

METHODS

Patients

We collected blood samples from 134 affected PCD subjects and family members belonging to 109 unrelated nuclear families. Ultrastructural analyses revealed an ODA defect in 47 PCD families, whereas only nine families exhibited an IDA defect (*see* the online supplement Figure E2). Twenty-one families had parental consanguinity and diagnosis of PCD was based on established criteria (1). Pedigrees of PCD families were compatible with autosomal recessive inheritance. The geographic origin was Europe (Germany, 46; United Kingdom, 10; Switzerland, 10; Hungary, 8; Belgium, 1; The Netherlands, 2; Austria, 2; and Sweden, 1) and North America, 29. To establish representative prevalence data, we added the 25 PCD families analyzed in our previous study (19; *see* Figures E3 and E4). In addition, 60 unrelated North American patients were screened for the founder mutation 10815delT (32 had ODA defects, 3 had IDA defects, 2 had central pair defects, 9 had normal dynein arms). Informed consent was obtained using protocols approved by the Institutional Ethics Review Board at the University of Freiburg and collaborating institutions.

Haplotype Analysis

Haplotype analysis was performed in consanguineous families and families with at least two affected individuals. Two highly polymorphic intragenic microsatellite markers (MIC-DNAH5-1; MIC-DNAH5-3) were tested as described previously (19). Using sequence information of 60 single-nucleotide polymorphisms, we deduced haplotypes based on genotypes of patients with homozygous mutations (F373, UNCB, UNC47, UNC83) and the assumption of existing founder haplotypes in patients with PCD originating from different families.

Mutational Analysis

Genomic DNA was isolated by standard methods directly from blood samples or from lymphocyte cultures after Epstein-Barr virus transformation. Amplification of 80 genomic fragments comprising all 79 exons and one alternative first exon of *DNAH5* was performed as described previously (19). Sequence data were evaluated using the Codoncode software (CodonCode Corporation, Dedham, MA). To aid identification of frequent polymorphisms, we sequenced samples from 10 healthy control subjects. All identified mutations were confirmed by repeated sequencing. We screened 140 control chromosomes originating from healthy white individuals for the presence of missense and facultative splicing mutations. Segregation analyses and screening of control subjects were performed by restriction analysis, denaturing high-performance liquid chromatography, or sequencing.

cDNA Analysis of the 1730G>C Mutation

Total RNA was isolated by the TRIzol method or RNeasy Mini Kit (Qiagen, Valencia, CA) from respiratory epithelial cells obtained by nasal brush biopsies. First-strand cDNA synthesis was performed with a SuperScriptII RNase kit (Invitrogen, Carlsbad, CA). As a control, reverse transcriptase was omitted in a parallel reaction. To test whether the splice donor site of exon 13 is mutated, a cDNA fragment corresponding to exons 12–14 was amplified by polymerase chain reaction (PCR; 52°C annealing temperature) with primers spanning the junctions of exons 11/12 and 14–15 (F: 5'-TAA ATA CCA GGG CAT TGT GG-3', R: 5'-TTC TTC AAT TTG CCG AAG C-3'), respectively. Products were subjected to second-round amplification, cloned, and subsequently sequenced (*see* Figure E5).

High-Speed Video Analysis of Cilia Beating

Ciliary beat frequency and beating pattern were assessed with the Sisson Ammons Video Analysis (SAVA) system as described previously (21). We examined nasal brush biopsies from five patients with PCD (OP40, OP51, F718, OP54, OP31) in which novel *DNAH5* mutations were detected.

Immunofluorescence Studies of Respiratory Epithelial Cells

Respiratory epithelial cells from patients OP9, OP31, OP40, OP51, OP54, F718, UNC29, and UNC35 were obtained by transnasal brush biopsy and processed for high-resolution immunofluorescence imaging as described previously (21).

RESULTS

Mutational Analysis of *DNAH5*

We have previously shown that *DNAH5* mutations cause PCD and randomization of left–right asymmetry (19) (*see* Figure E3). To determine the frequency of *DNAH5* mutations in PCD, we screened an additional large international cohort of 109 PCD families (*see* Figure E2). In 26 PCD families, haplotype analyses were not consistent with linkage to the *DNAH5* locus, indicating that *DNAH5* mutations most likely are not responsible for the disease phenotype in these families. Sequencing of all coding exons, including the exon/intron boundaries in the remaining 83 families, revealed 33 novel *DNAH5* mutations in patients with PCD from 30 families or 34 affected patients (Figure 1). In addition, the two previously reported frameshift mutations, 5563_5564insA and 8440-8447delGAACCAA, were also identified in three and one patients, respectively (19). In only eight families, one mutant allele was detected and the second mutant allele remained unidentified (Table 1). The observed mutational changes fell into two major groups: truncating ($n = 27$; 77%) and missense mutations ($n = 8$; 23%). The 33 novel mutations included 12 nonsense mutations, eight frameshift mutations, three obligatory and two facultative splicing mutations (1730G>C; IVS76+5G>A), as well as eight missense mutations.

The missense and facultative splicing mutations were absent in 140 control chromosomes, and cosegregation of the mutations with disease phenotypes was confirmed (Table 1). For facultative splicing mutation (1730G>C), aberrant splicing was confirmed by reverse transcriptase–PCR analysis (*see below*). In the IV-S76+5G>A mutation, a conserved (80%) base pair is affected, which predicts aberrant splicing. We considered the IV-S76+5G>A exchange to represent a mutation, because this DNA variant was found twice in the PCD population but was absent in the control population. In addition, cosegregation within the two PCD families carrying the IVS76+5G>A was noted and deduced haplotype analysis (*see below*) was consistent with a founder mutation.

The eight identified missense mutations affect amino acid residues that have been evolutionarily conserved in the mouse (AF466704) and/or *C. reinhardtii* (U15303) *DNAH5* orthologs, respectively. Two of these mutations are located within known functional domains of *DNAH5* (Figure 1). The mutation W3409S is located in the microtubule binding site and S2264N resides in the P2-loop domain of the protein.

We observed clustering of mutations within five exons harboring 27 mutant alleles (52%) of the 52 detected mutant alleles. Clinical findings of PCD patients with *DNAH5* mutations are depicted in Table E2. No genotype–phenotype correlations have been identified.

The 1730G>C Mutation Results in Abnormal Splicing

In Patient UNC75 II1, we detected the heterozygous 1730G>C mutation, which affects an 80% conserved base pair of the splice donor site of exon 13. To test whether this mutation indeed affects splicing, we performed reverse transcriptase–PCR, which showed two fragments corresponding to the wild-type (535 bp) and a variant (449 bp) allele, consistent with heterozygosity (*see* Figure E5). Cloning and subsequent sequencing of the PCR products revealed that the 449-bp product fuses exon 12 out of frame to exon 14 and therefore lacks exon 13, whereas the 535-bp product coincides with the wild-type fragment. We conclude that the mutant splice site cannot be recognized by the splicing machinery, leading to skipping of exon 13, which predicts premature termination of translation because of out-of-frame fusion.




Figure 1. Distribution of novel and published *DNAH5* mutations. *Top:* schematic presentation of the genomic structure of *DNAH5*. Exons are numbered and indicated by *black boxes*. *Open boxes* represent untranslated regions. ATG, start codons, TAA, stop codon. Intron sizes are not drawn to scale. The positions of the intronic *DNAH5* mutations are indicated by *vertical lines*. *Bottom:* schematic drawing of *DNAH5*. The P-loop domains and the microtubule binding domain are shown. The positions of all identified exonic *DNAH5* mutations are indicated by *vertical lines*. Mutations that were detected in several unrelated families are marked by an *asterisk* (≥ 4 PCD families) and *dagger* (2 PCD families). Mutations that were identified in our previous study are indicated by *gray boxes* (19). Novel mutations are depicted in *red*.

DNAH5 Mutations Cause PCD with ODA Defects

All patients carrying *DNAH5* mutations that were studied by transmission electron microscopy ($n = 22$) exhibited ODA defects. We have previously shown that at least two distinct ODA complexes are found within human respiratory cilia and that both contain *DNAH5* and exhibit a distinct regional distribution along the ciliary axoneme (21). In addition, we could demonstrate in three patients carrying homozygous *DNAH5* mutations (5563_5564insA, 8440-8447delGAACCAAA, and IVS74-1G>C) that the mutated *DNAH5* proteins were expressed but were absent from the entire ciliary axoneme, and instead accumulated at the ciliary base. This finding indicates that these *DNAH5* mutations affect assembly of both ODA types. Here, we studied an additional eight individuals with *DNAH5* mutations for *DNAH5* localization in respiratory cells that were obtained by nasal brushing biopsy. In all cases, we found expression of mutant *DNAH5*. In seven individuals, we found a complete absence of mutant *DNAH5* from the ciliary axoneme and accumulation at the ciliary base and within the cytoplasm (Figure 2B), as reported previously (21). However, one patient (F718 II1) carrying compound heterozygous mutations, which affect splicing at the 3'-end of the gene (IVS 75 and 76), showed absence of *DNAH5* only from the distal part of the ciliary axonemes (Figure 2C) and remaining *DNAH5* staining in the proximal part, indicating that assembly of one type of ODA is at least partially preserved. We previously observed this pattern of aberrant *DNAH5* staining only in patients with *DNAH1* mutations (21). Interestingly, in nine individuals with isolated IDA defects, we did not find *DNAH5* mutations by sequence analysis. Thus, mutations of *DNAH5* encoding an ODA heavy chain most likely affect only assembly of ODA complexes, but might not affect IDA assembly. In the preselected subpopulation of patients with PCD with documented ODA defects demonstrated by electron microscopy and/or high-resolution immunofluorescence microscopy ($n = 47$), *DNAH5* mutations were identified in 53% of patients.

We have previously shown that cilia with ODA defects are immotile or only show flickering movements (21). We analyzed patients with *DNAH5* mutations by high-speed videomicroscopy ($n = 5$). Two of these patients (OP54, OP51) had completely immotile cilia in all examined respiratory epithelial cells. In three patients (OP31, OP40, F718), most respiratory cilia were immotile; however, some cilia showed severely altered motility with stiff movements and low amplitudes.

DNAH5 Founder Mutations

The mutations 10815delT, 5563_5564insA, 13458_13459insT, IVS76+5G>A, 8528T>C, and 8440-8447delGAACCAAA were found in seven, three, four, two, two, and one families, respectively. Two of these mutations (5563_5564insA, 8440-8447delGAACCAAA) were reported previously (19). To address the question of whether these mutations were derived from a common ancestor (founder) or occurred independently, we took advantage of the high number of single-nucleotide polymorphisms present in the 250-kb *DNAH5* locus to deduce the haplotypes associated with the identified mutations. Because of the large dataset, results representative ($n = 39$) of 60 single-nucleotide polymorphisms are depicted in Figure E1. The haplotype analysis was facilitated, because some affected individuals carried homozygous mutations (5563_5564insA, 10815delT, 13458_13459insT). Analysis of the deduced haplotypes indicates that the mutations 10815delT (UNCB, UNC47, UNC35, UNC74, UNC29, UNC102, OP19), IVS76+5G>A (UNC76, F718), and 8528T>C (UNC35, UNC48) are founder mutations (see Figure E1). Interestingly, for the mutations 5563_5564insA and 13458_13459insT, we could show that the mutational events most likely occurred independently in some of the families, whereas in other families, they are consistent with founder mutations (see Figure E1). Consistent with these findings, the 5563_5564insA mutation was identified in patients with PCD from Europe (OP31 II1) and North America (UNC72 and UNC76) who share

TABLE 1. *DNAH5* MUTATIONS IN PRIMARY CILIARY DYSKINESIA

Family	Patient	Origin	Exon	DNA Change	Protein Change	ODA Defect	Segregation
Homozygous							
OP36	II1	Germany	[36]+[36]	[6037C>T]	[R2013X]	n.a	P + M
UNC47	II1	United States	[63]+[63]	[10815delT]	[P3606HfsX23]	EM	n.d. + M
UNCB	II1	United States	[63]+[63]	[10815delT]	[P3606HfsX23]	EM	n.d.
UNC83	II1	United States	[77]+[77]	[13458_13459insT]	[N4487fsX1]	EM	n.d.
Compound							
UNC29	II1	United States	[3]+[63]	[232C>T]+[10815delT]	[R78X]+[P3606HfsX23]	EM + IF	P + M
UNC59	II1	United States	[7]+[12]	[832delG]+[1627C>T]	[A278RfsX27]+[Q543X]	EM	P + M
OP54	II1	Switzerland	[17]+[48]	[IVS17+2T>C]+[7914_7915insA]	splicing-mut.+[R2639TfsX19]	EM + IF	P + M
UNC45	II1	United States	[25]+[77]	[3905delT]+[13458_13459insT]	[L1302RfsX19]+[N4487fsX1]	EM	M + P
OP31	II1	Germany	[27]+[34]	[IVS27+1G>A]+[5563_5564insA]	splicing-mut.+[I1855NfsX6]	IF	P + M
OP40	II1	Germany	[32]+[77]	[5147G>T]+[13458_13459insT]	[R1716L]+[N4487fsX1]	IF	M + n.d.
UNC72	II1	United States	[33]+[34]	[5281C>T]+[5563_5564insA]	[R1761X]+[I1855NfsX6]	EM	n.d.
UNC34	II1	United States	[33]+[60]	[5482C>T]+[10226G>C]	[Q1828X]+[W3409S]	EM	P + M
OP19	III1	Germany	[34]+[63]	[5599_5600insC]+[10815delT]	[L1867PfsX35]+[P3606HfsX23]	n.a.	P + M
UNC76	II1	United States	[34]+[76]	[5563_5564insA]+[IVS76+5G>A]	[I1855NfsX6]+splicing-mut.	EM	n.d.
OP51	II1,II2	Switzerland	[41]+[76]	[6791C>A]+[13194_13197delCAGA]	[S2264N]+[D4398EfsX16]	EM + IF	M + n.d.
UNC32	II1	United States	[43]+[45]	[7039G>A]+[7502G>C]	[E2347K]+[R2501P]	EM	n.d.
F668	II1	Germany	[49]+[49]	[8029C>T]+[8167C>T]	[R2677X]+[Q2723X]	n.a.	P + M
UNC31	II1,II2	United States	[50]+[77]	[8404C>T]+[13426C>T]	[Q2802X]+[R4476X]	EM	M + n.d.
UNC35	II1	United States	[51]+[63]	[8528T>C]+[10815delT]	[F2843S]+[P3606HfsX23]	EM + IF	M + n.d.
UNC102	II1,II2,II3	United States	[63]+[77]	[10815delT]+[13486C>T]	[P3606HfsX23]+[R4496X]	EM	P + M
UNC74	II1	United States	[63]+[77]	[10815delT]+[13458_13459insT]	[P3606HfsX23]+[N4487fsX1]	EM	M + n.d.
F718	II1	Germany	[76]+[76]	[IVS75-2A>T]+[IVS76+5G>A]	splicing-mut.+splicing-mut.	IF	n.d. + M
Heterozygous							
UNC81	II1	United States	[3]+n.d.	[252T>G]+n.d.	[Y84X]+n.d.	EM	n.d.
UNCK	II1	United States	[11]+n.d.	[1426_1427delTT]+n.d.	[F476SfsX26]+n.d.	EM	n.d.
UNC75	II1	United States	[13]+n.d.	[1730G>C]+n.d.	splicing-mut.+n.d.	EM	P
OP9	II1	Hungary	[50]+n.d.	[8440_8447delGAACAAA]+n.d.	[E2814fsX1]+n.d.	EM + IF	P
CH-6475	II1	Switzerland	[50]+n.d.	[8314C>T]+n.d.	[R2772X]+n.d.	n.a.	n.d.
UNC48	II1	United States	[51]+n.d.	[8528T>C]+n.d.	[F2843S]+n.d.	EM	M
OP3	II1	Germany	[67]+n.d.	[11528C>T]+n.d.	[S3843L]+n.d.	n.a.	n.d.
UNC87	II1	United States	[73]+n.d.	[12614G>T]+n.d.	[G4205V]+n.d.	EM	M

Definition of abbreviations: EM = electron microscopy; IF = immunofluorescence; M = maternal; mut. = mutation; n.a. = not available; n.d. = not determined; ODA = outer dynein arm; P = paternal.

the same haplotype. In contrast, their haplotype differs from the haplotype of an Arab patient with PCD (F373), who carries the 5563_5564insA mutation reported previously (19). Similarly, we found three North American patients with PCD (UNC45, UNC74, and UNC83) with identical deduced haplotypes carrying the 13458_13459insT mutation and one patient with PCD from Europe (OP40 II1) with a different deduced haplotype. The 10815delT founder mutation was found in six United States' PCD families and one European PCD family. To confirm that this mutation is especially prevalent within the United States' PCD population, we screened 60 patients in the United States and identified in four PCD families the 10815delT founder mutation. In two of these families, ultrastructural analysis was available and showed ODA defects.

Prevalence of *DNAH5* Mutations

By adding 25 previously analyzed PCD families (Germany [n = 10], United Kingdom [n = 7], Belgium [n = 2], and North America [n = 6]) to the 109 analyzed PCD families, we calculated the frequency of mutations in all 134 apparently unrelated PCD families that have been thus far analyzed for *DNAH5* mutational status (19) (see Figures E2–E4). In these 134 PCD families from Europe and North America, 38 families (51 affected individuals) were detected carrying *DNAH5* mutations, which represents an overall frequency of 28%. All patients with PCD with *DNAH5* mutations were white. In the subpopulation of patients with PCD with documented ODA defects demonstrated by electron microscopy and/or high-resolution immunofluorescence microscopy (n = 65), *DNAH5* mutations were identified in 49% of

patients. To date, a total of 66 mutant alleles are known. Mutations seem to cluster within the five exons 34, 50, 63, 76, and 77, which harbor 31 (47%) mutant alleles (see Table E1 and Figure E4). In 20 (53%) PCD families carrying *DNAH5* mutations, at least one mutation within these five exons was detected.

DISCUSSION

The most frequent ultrastructural defects in PCD affect the composition of dynein arms, which are responsible for cilia and sperm tail movement (11, 22–24). Linkage studies suggest extensive genetic heterogeneity in PCD (20). So far, only two genes, *DNAI1* and *DNAH5*, have been clearly linked to autosomal recessive forms of PCD (12, 19). *DNAH11* mutations possibly also cause PCD (25). All three genes encode for components of ODA complexes.

This study determined the frequency, distribution, and the phenotype associated with *DNAH5* mutations. *DNAH5* is a large gene comprising 79 exons and one alternative first exon and encodes a heavy chain of the ODA. We have recently shown that recessive *DNAH5* mutations are responsible for PCD characterized by ODA defects (19). The murine ortholog *Mdnah5* (alias *Dnahc5*) is expressed in the node during early embryonic development, in the respiratory tract and in testes, which is consistent with disease manifestations in PCD (19, 26). In this current study, we report analysis of an additional PCD cohort comprising 109 PCD families and detected 33 distinct novel mutations and two mutations reported previously (Table 1). Mutations were scattered along the entire coding region (Figure 1).




Figure 2. Mis-localization of mutant DNAH5 in respiratory epithelial cells from patients with primary ciliary dyskinesia carrying *DNAH5* mutations. Confocal immunofluorescence analysis of human respiratory epithelial cells with anti-DNAH5 antibodies (red) and with antibodies against axoneme-specific acetylated α -tubulin (green) as control (21). Nuclei were stained with Hoechst 33342 (blue). (A) In respiratory epithelial cells from healthy probands, DNAH5 localizes along the entire length of the axonemes and at the microtubule organizing centers. (B) In respiratory epithelial cells from patient OP40 II1, carrying the compound heterozygous *DNAH5* mutations R1716L and 4487NfsX1, mutant DNAH5 is expressed and correctly targeted to the ciliary base where it accumulates. In contrast to healthy control subjects, we observed complete absence of mutant DNAH5 from the ciliary axonemes. (C) In Patient F718

II1, who carries compound heterozygous *DNAH5* mutations affecting splicing at the 3'-end of the gene, mutant DNAH5 is absent from the distal part of the ciliary axonemes but is still detectable within the proximal part.

Most of the identified mutations were nonsense mutations, but frameshift, splicing, and missense mutations were also found. The most common *DNAH5* mutations clustered within only five exons, 34, 50, 63, 76, and 77, which harbor *DNAH5* mutations in 53% of a total of 134 analyzed PCD families (see Table E1 and Figure E4). The increased frequency of mutant alleles in only 5 of the 80 known coding exons of *DNAH5* might help to develop a fast and cost-effective genetic assay for genetic diagnosis in the future. Six mutations (5563_5564insA, 10815delT, 13458_13459insT, 8440-8447delGAACCAAA, 8528T>C, and IVS76+5G>A) were identified in more than one unrelated PCD family. Three of the identified *DNAH5* mutations (5563_5564insA, 10815delT, and 13458_13459insT) were found in four, seven, and four families, respectively. Based on the large number of single-nucleotide polymorphisms within the *DNAH5* locus, we were able to analyze whether these sequence variants occurred because of independent mutational processes or are related to ancestral founders. These analyses indicate that 10815delT, 8528T>C, and IVS76+5G>A are founder mutations (Figure E1). For two of the other mutations (5563_5564insA and 13458_13459insT), we found a more complex situation, where, in some PCD families, the mutations probably occurred independent from each other and, in others, deduced haplotypes suggest a common ancestor (Figure E1). Importantly, we could demonstrate that the 10815delT mutation is especially prevalent in the white PCD population in the United States. We confirmed that genetic screening for this mutation is notably useful in United States' PCD families and identified additional four PCD families in a cohort of 60 analyzed PCD families in the United States.

Previously, we studied the axonemal ultrastructure in several patients with PCD carrying *DNAH5* mutations. All patients exhibited deficiency of ODAs (19, 26), which is consistent with

DNAH5 constituting one component of the large multimeric ODA complexes. Here, evaluation of electron microscopic data from a large cohort of patients ($n = 109$) with *DNAH5* mutations ($n = 22$) confirmed ultrastructural ODA defects in all cases, including patients carrying missense mutations. Interestingly, we did not find *DNAH5* mutations in patients without ODA defects by electron microscopy. Importantly, patients with PCD with isolated IDA defects did not harbor *DNAH5* mutations. On the basis of these observations, we conclude that *DNAH5* mutations regularly disturb the correct assembly of ODA complexes.

To gain more insight into the molecular pathology of PCD caused by *DNAH5* mutations, we analyzed respiratory cells obtained by nasal brushing biopsy from eight patients with PCD with recessive *DNAH5* mutations. We have previously shown that human respiratory cilia contain at least two ODA types, which differ in their content of dynein heavy chains and which show differences concerning their regional distribution along the ciliary axoneme: type 1 (DNAH9-negative and DNAH5-positive; proximal ciliary axoneme) and type 2 (DNAH9- and DNAH5-positive; distal ciliary axoneme) (21). In the study presented here, we show by high-resolution immunofluorescence imaging that, regardless of the mutational background, mutant DNAH5 proteins are expressed in respiratory epithelial cells from patients with PCD, but are not appropriately localized along the axonemal shaft (Figure 2). Consistent with the available ultrastructural data exhibiting ODA deficiency, we identified in all eight analyzed patients with PCD with *DNAH5* mutations mislocalization of mutant DNAH5 with accumulation at the microtubule organizing centers. Because all mutations result in mutant DNAH5 with preservation of the N-terminal third of the protein, we assume that this region contains a domain responsible for correct targeting of DNAH5 to the microtubule organizing

centers. In all but one patient with PCD with *DNAH5* mutations, we found complete absence of mutant *DNAH5* from the respiratory ciliary axonemes, as reported previously in three patients with PCD with *DNAH5* mutations (21). In these cases, mutations affect assembly of both ODA complexes that contain *DNAH5* (Figure 2B). In contrast, in one patient (F718), we found that mutant *DNAH5* was absent from the distal ciliary axoneme, but was preserved within the proximal ciliary axoneme (Figure 2C). This staining pattern clearly demonstrates that, in this patient, mutant *DNAH5* can be correctly targeted to the site of proximally located ODA complexes. F718 carries compound heterozygous mutations located at the 3'-end of *DNAH5* (IVS 75 and 76), which both predict aberrant splicing. This indicates that the C-terminal region of *DNAH5* is important for assembly of ODA type 2. Such a staining pattern was so far not observed in patients with *DNAH5* mutations but only in patients carrying *DNAH1* mutations (21).

The primary goal of current therapy for patients with PCD is prevention of progressive lung damage (27). The strict treatment of infections of the upper and lower airways, appropriate therapy regarding chronic otitis media, and consequent physical therapy may result in increased quality of life and retardation of chronic lung failure. However, therapeutic options that correct cilia dysmotility to restore mucociliary clearance are currently not available. Recently, it has been shown that aminoglycoside antibiotics are able to suppress the usage of premature termination codons by permitting translation to continue to the normal termination of translation (28, 29). Clinical studies using pharmacogene therapy in patients with cystic fibrosis carrying premature nonsense mutations in the *CFTR* gene provided compelling evidence that the aminoglycoside gentamicin can suppress stop mutations in the *CFTR* gene and restore *CFTR* function (30–32). Here, we found *DNAH5* nonsense mutations in a high proportion of patients with PCD. This opens the possibility to use pharmacogene therapy to correct the primary defect in these patients with PCD. In future *in vitro* studies, we will address this question by treating primary human respiratory epithelial cells from patients with PCD carrying nonsense *DNAH5* mutations with aminoglycosides. Possibly, this will lead to the development of novel therapeutic strategies in PCD.

A recent work studying a large cohort of patients with PCD for the presence of *DNAH1* mutations shows that mutations in this gene can be identified in 13% of PCD families with ODA defects (M.A. Zariwala and coworkers, submitted for publication). To date, 134 PCD families have been screened for mutations in *DNAH5* and recessive mutations were identified in 49% of PCD families with ODA defects (see Figure E4). Thus, although PCD represents a genetically heterogeneous disorder, *DNAH5* dysfunction appears to be a major cause of PCD with ODA defects.

Conflict of Interest Statement: None of the authors has a financial relationship with a commercial entity that has an interest in the subject of this manuscript.

Acknowledgment: The authors thank the patients and their families for their participation in this study. They thank the German patient support group "Kartagener Syndrom und Primaere Ciliaere Dyskinesie e.V." and the U.S. PCD Foundation. They thank Anil Mehta (University of Dundee, UK) for helpful discussion at the 2005 Gordon Conference "Cilia, Mucus and Mucociliary Interactions." They also thank R. Melkaoui, J. Kalnitski, P. Pausch, J. Thiel, and S. Klages for technical assistance, and J. Freiherst (Hannover), W. Henn (Saarland), S. Illing (Stuttgart), N. Konietzko (Essen), B. Morass (Innsbruck), S. Reitmayr (Wien), E. Rietschel (Köln), S. Szczepanski (Osnabrück), and M. Wessels (Belgium) for contributing clinical information and patient samples.

References

1. Ibanez-Tallon I, Heintz N, Omran H. To beat or not to beat: roles of cilia in development and disease. *Hum Mol Genet* 2003;12:27–35.

2. El Zein L, Omran H, Bouvagnet P. Lateralization defects and ciliary dyskinesia: lessons from algae. *Trends Genet* 2003;19:162–167.
3. Afzelius BA, Mossberg B, Bergström SE. Immotile cilia syndrome (primary ciliary dyskinesia), including Kartagener syndrome. In: Scriver CS, Beaudet AL, Valle D, Sly WS, Childs B, Kinzler KW, Vogelstein B, editors. *The metabolic and molecular bases of inherited disease*, 8th ed. Vol. 3. New York: McGraw-Hill; 2001. pp. 4817–4827.
4. Nonaka S, Tanaka Y, Okada Y, Takeda S, Harada A, Kanai Y, Kido M, Hirokawa N. Randomization of left-right asymmetry due to loss of nodal cilia generating leftward flow of extraembryonic fluid in mice lacking KIF3B motor protein. *Cell* 1998;95:829–837.
5. Afzelius BA, Eliasson R. Male and female infertility problems in the immotile-cilia syndrome. *Eur J Respir Dis Suppl* 1983;127:144–147.
6. Munro NC, Currie DC, Lindsay KS, Ryder TA, Rutman A, Dewar A, Greenstone MA, Hendry WF, Cole PJ. Fertility in men with primary ciliary dyskinesia presenting with respiratory infection. *Thorax* 1994; 49:684–687.
7. Coren ME, Meeks M, Morrison I, Buchdahl RM, Bush A. Primary ciliary dyskinesia: age at diagnosis and symptom history. *Acta Paediatr* 2002; 91:667–669.
8. Holzbaur EL, Vallee RB. Dyneins: molecular structure and cellular function. *Annu Rev Cell Biol* 1994;10:339–372.
9. Witman GB, Wilkerson CG, King SM. The biochemistry, genetics and molecular biology of flagellar dynein. In: Hyams JS, Lloyd CW, editors. *Microtubules*. New York: Wiley-Liss; 1994. pp. 229–249.
10. DiBella LM, King SM. Dynein motors of the *Chlamydomonas* flagellum. *Int Rev Cytol* 2001;210:227–268.
11. Jorissen M, Willems T, Van der Schueren B, Verbeken E, De Boeck K. Ultrastructural expression of primary ciliary dyskinesia after ciliogenesis in culture. *Acta Otorhinolaryngol Belg* 2000;54:343–356.
12. Pennarun G, Escudier E, Chapelin C, Bridoux AM, Cacheux V, Roger G, Clement A, Goossens M, Amselem S, Duriez B. Loss-of-function mutations in a human gene related to *Chlamydomonas reinhardtii* dynein IC78 result in primary ciliary dyskinesia. *Am J Hum Genet* 1999;65:1508–1519.
13. Zariwala M, Noone PG, Sannuti A, Minnix S, Zhou Z, Leigh MW, Hazucha M, Carson JL, Knowles MR. Germline mutations in an intermediate chain dynein cause primary ciliary dyskinesia. *Am J Respir Cell Mol Biol* 2001;25:577–583.
14. Guichard C, Harricane MC, Lafitte JJ, Godard P, Zaegel M, Tack V, Lalau G, Bouvagnet P. Axonemal dynein intermediate-chain gene (*DNAH1*) mutations result in situs inversus and primary ciliary dyskinesia (Kartagener syndrome). *Am J Hum Genet* 2001;68:1030–1035.
15. Zito I, Downes SM, Patel RJ, Cheetham ME, Ebenezer ND, Jenkins SA, Bhattacharya SS, Webster AR, Holder GE, Bird AC, et al. RPGR mutation associated with retinitis pigmentosa, impaired hearing, and sinorespiratory infections. *J Med Genet* 2003;40:609–615.
16. Iannaccone A, Breuer DK, Wang XF, Kuo SF, Normando EM, Filippova E, Baldi A, Hiriyanna S, MacDonald CB, Baldi F, et al. Clinical and immunohistochemical evidence for an X linked retinitis pigmentosa syndrome with recurrent infections and hearing loss in association with an RPGR mutation. *J Med Genet* 2003;40:e118.
17. Moore A, Escudier E, Roger G, Tamalet A, Pelosse B, Marlin S, Clement A, Geremek M, Delaisi B, Bridoux AM, et al. RPGR is mutated in patients with a complex X-linked phenotype combining primary ciliary dyskinesia and retinitis pigmentosa. *J Med Genet* 2006;43:326–333.
18. Omran H, Haffner K, Volkel A, Kuehr J, Ketelsen U-P, Ross UH, Konietzko N, Wienker T, Brandis M, Hildebrandt F. Homozygosity mapping of a gene locus for primary ciliary dyskinesia on chromosome 5p and identification of the heavy dynein chain *DNAH5* as a candidate gene. *Am J Respir Cell Mol Biol* 2000;23:696–702.
19. Olbrich H, Haffner K, Kispert A, Volkel A, Volz A, Sasmaz G, Reinhardt R, Hennig S, Lehrach H, Konietzko N, et al. Mutations in *DNAH5* cause primary ciliary dyskinesia and randomization of left-right asymmetry. *Nat Genet* 2002;30:143–144.
20. Blouin JL, Meeks M, Radhakrishna U, Sainsbury A, Gehring C, Sail GD, Bartoloni L, Dombi V, O'Rawe A, Walne A, et al. Primary ciliary dyskinesia: a genome-wide linkage analysis reveals extensive locus heterogeneity. *Eur J Hum Genet* 2000;8:109–118.
21. Fliegauf M, Olbrich H, Horvath J, Wildhaber JH, Zariwala MA, Kennedy M, Knowles MR, Omran H. Mis-localization of *DNAH5* and *DNAH9* in respiratory cells from primary ciliary dyskinesia patients. *Am J Respir Crit Care Med* 2005;171:1343–1349.
22. Afzelius BA. A human syndrome caused by immotile cilia. *Science* 1976; 193:317–319.
23. Geremek M, Witt M. Primary ciliary dyskinesia: genes, candidate genes and chromosomal regions. *J Appl Genet* 2004;45:347–361.

24. Noone PG, Leigh MW, Sannuti A, Minnix SL, Carson JL, Hazucha M, Zariwala MA, Knowles MR. Primary ciliary dyskinesia: diagnostic and phenotypic features. *Am J Respir Crit Care Med* 2004;15:459–467.
25. Bartoloni L, Blouin JL, Pan Y, Gehrig C, Maiti AK, Scamuffa N, Rossier C, Jorissen M, Armengot M, Meeks M, *et al*. Mutations in the DNAH11 (axonemal heavy chain dynein type 11) gene cause one form of situs inversus totalis and most likely primary ciliary dyskinesia. *Proc Natl Acad Sci USA* 2002;99:10282–10286.
26. Kispert A, Petry M, Olbrich H, Volz A, Ketelsen UP, Horvath J, Melkaoui R, Omran H, Zariwala M, Noone PG, *et al*. Genotype-phenotype correlations in PCD patients carrying DNAH5 mutations. *Thorax* 2003;58:552–554.
27. Bush A, Cole P, Hariri M, Mackay I, Phillips G, O'Callaghan C, Wilson R, Warner JO. Primary ciliary dyskinesia: diagnosis and standards of care. *Eur Respir J* 1998;12:982–988.
28. Davies J, Goorini L, Davis D. Misreading of RNA codewords induced by aminoglycoside antibiotics. *Mol Pharmacol* 2002;1:93–106.
29. Martin R, Mogg AE, Heywood LA, Nitschke L, Burke JF. Aminoglycoside suppression at AUG, UAA, and UGA codons in *E. coli* and human tissue culture cells. *Mol Gen Genet* 1979;217:411–418.
30. Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. *Nat Med* 1996;4:467–469.
31. Bedwell DM, Kaenjak A, Benos DJ, Bebok Z, Bubien JK, Hong J, Tousson A, Clancy JP, Sorscher EJ. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. *Nat Med* 1997;3:1280–1284.
32. Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, Aviram M, Bdolah-Abram T, Bebok Z, Shushi L, *et al*. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. *N Engl J Med* 2003;349:1433–1441.